Clinical Trial Detail

NCT ID NCT02845297
Title Phase 2 Study of Azacitidine in Combination With Pembrolizumab in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients and in Newly Diagnosed Older (?65 Years) AML Patients
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors Sidney Kimmel Comprehensive Cancer Center
Indications

acute myeloid leukemia

Therapies

Azacitidine + Pembrolizumab

Age Groups: adult

No variant requirements are available.